Navigation Links
Bioforce Receives American Botanical Council's Tyler Award
Date:3/5/2012

AUSTIN, Texas, March 5, 2012 /PRNewswire-USNewswire/ -- The nonprofit American Botanical Council has announced that Bioforce AG is the recipient of its annual Varro E. Tyler Commercial Investment in Phytomedicinal Research Award. Bioforce AG is a Swiss herbal products manufacturer that spends approximately $1 million on pharmacological and clinical research each year, according to company sources.

(Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO)

"We were surprised and honored to receive this prestigious award and, at the same time, also proud to see that our efforts to invest in research are acknowledged," said Andreas Suter, head of medicine and product development at Bioforce AG. "We share [Prof. Tyler's] views on phytotherapy, that the use [of] herbal medicine must not only be based on fascination but also on sound scientific data."

"Bioforce is a rare company in the global herbal community," said ABC Founder and Executive Director Mark Blumenthal. "The company employs the highest quality levels of sustainable farming practices while embracing the rich traditions of European herbal medicine, combining it with modern scientific research. These concepts—sustainability, tradition, and research—are at the core of the company's ethics and practices. Bioforce's continued investment in research is consistent with Prof. Varro Tyler's wish that all herb companies dedicate a portion of their revenues to researching the mechanisms and/or the efficacy of their botanical products."

The late Prof. Tyler—who has been described as one of the most respected men in late 20th century herbal medicine and pharmacognosy (the study of medicines of natural origin, usually from plants)—was an early trustee of ABC and the dean of the College of Pharmacy and Pharmaceutical Sciences at Purdue University and vice-president of academic affairs
'/>"/>

SOURCE American Botanical Council
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
2. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
8. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
9. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... and RARITAN, N.J. , ... multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) ... investigational, human anti-CD38 monoclonal antibody – achieved an ... CI, 20.8-38.9), as assessed by an independent review ... The ORR was consistent among the pre-specified subgroups ...
(Date:5/29/2015)... , May 29, 2015 BerGenBio ... today announces that an abstract on the latest data ... of the Axl receptor tyrosine kinase, and BGB10C9, an ... has been published in conjunction with the 2015 American ... Chicago , May 29 - June 2, ...
(Date:5/29/2015)... Market Publishers Ltd and Shanghai ... partnership agreement for quality market research promotion on ... sell research reports worked out by Chem-Report. , ... upon the agreement: “Chem-Report is a Chinese company ... chemical markets on global and country levels. The ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... Calif., Oct. 17 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... novel anticancer therapeutics, today announced that the,company ... Conference on,Molecular Targets and Cancer Therapeutics. This ... in San Francisco, California. Preliminary data ...
... call Wednesday, October 24, at 1:30 p.m. EDT, ... AVGN ), a biopharmaceutical company developing innovative ... its quarterly,conference call to discuss third quarter results ... (10:30 a.m. PDT). Kenneth Chahine, Chief Executive,Officer, and ...
... Calif. Carbon nanotubes have been employed for a ... and membranes. , While they have proven useful for ... going on at the molecular level. For example, how ... other on the atomic scale" Answering this question could ...
Cached Biology Technology:Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Researchers measure carbon nanotube interaction 2
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... macrophages, immune cells that can engulf and poison bacteria ... A new study from the University of Illinois disproves ... PLoS ONE , shows that macrophages focus their most ... targets outside the cytoplasm. Macrophages are voracious eaters ...
... research institutes, announced today the launch of three ... in extreme environments. The three selected genomes are ... and emperor penguin, and one altiplano animal: the ... carried out using Next-generation sequencing technologies, which have ...
... and drainage. Blood vessels feeding the tissues bring in ... While much is known about how blood vessels are ... Now though, Norrmn et al. have identified two of ... mouse embryo. The engineers are the transcription ...
Cached Biology News:New study overturns orthodoxy on how macrophages kill bacteria 2New study overturns orthodoxy on how macrophages kill bacteria 3Genome projects launched for three extreme-environment animals 2Genome projects launched for three extreme-environment animals 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... and Silencer Pre-designed siRNAs, which are already ...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: